RESUMEN
The COVID-19 pandemic has brought an unprecedented crisis to the global health sector1. When recovering COVID-19 patients are discharged in accordance with throat or nasal swab protocols using reverse transcription polymerase chain reaction (RT-PCR), the potential risk of re-introducing the infection source to humans and the environment must be resolved2,3,4. Here we show that 20% of COVID-19 patients, who were ready for a hospital discharge based on current guidelines, had SARS-CoV-2 in their exhaled breath ([~]105 RNA copies/m3). They were estimated to emit about 1400 RNA copies into the air per minute. Although fewer surface swabs (1.3%, N=318) tested positive, medical equipment frequently contacted by healthcare workers and the work shift floor were contaminated by SARS-CoV-2 in four hospitals in Wuhan. All air samples (N=44) appeared negative likely due to the dilution or inactivation through natural ventilation (1.6-3.3 m/s) and applied disinfection. Despite the low risk of cross environmental contamination in the studied hospitals, there is a critical need for strengthening the hospital discharge standards in preventing re-emergence of COVID-19 spread.
RESUMEN
Stopping COVID-19 is a priority worldwide. Understanding which cell types are targeted by SARS-CoV-2 virus, whether interspecies differences exist, and how variations in cell state influence viral entry is fundamental for accelerating therapeutic and preventative approaches. In this endeavor, we profiled the transcriptome of nine tissues from a Macaca fascicularis monkey at single-cell resolution. The distribution of SARS-CoV-2 facilitators, ACE2 and TMRPSS2, in different cell subtypes showed substantial heterogeneity across lung, kidney, and liver. Through co-expression analysis, we identified immunomodulatory proteins such as IDO2 and ANPEP as potential SARS-CoV-2 targets responsible for immune cell exhaustion. Furthermore, single-cell chromatin accessibility analysis of the kidney unveiled a plausible link between IL6-mediated innate immune responses aiming to protect tissue and enhanced ACE2 expression that could promote viral entry. Our work constitutes a unique resource for understanding the physiology and pathophysiology of two phylogenetically close species, which might guide in the development of therapeutic approaches in humans. Bullet pointsO_LIWe generated a single-cell transcriptome atlas of 9 monkey tissues to study COVID-19. C_LIO_LIACE2+TMPRSS2+ epithelial cells of lung, kidney and liver are targets for SARS-CoV-2. C_LIO_LIACE2 correlation analysis shows IDO2 and ANPEP as potential therapeutic opportunities. C_LIO_LIWe unveil a link between IL6, STAT transcription factors and boosted SARS-CoV-2 entry. C_LI
RESUMEN
Objective To patient who suffer from middle and late period carcinoma of esophagus radiation therapy and chemotherapy. Observe the effects and the side effects of radiation therapy and chemotherapy.Methods Radiation therapy and chemotherapy 60 examples and radiation therapy 60 examples,radiation use usually divide,DT 40 Gy reduce area of radiation therapy,aroid medulla,add DT 20～30 Gy,its finished after 6～7 weeks.radiation therapy and chemotherapy after 1 and 4 week,DDP 20 mg/d is used.CF 0.1/d ivgtt CF ivgtt 1/2 is used use 5-fu 500 mg/d.iv five days in a routine,every day use radiation therapy and chemotherapy.Results Radiation therapy and chemotherapy 1,2,3 year alive rate are 67%,46%,34%,radiation therapy 1,2,3 year alive rate are 52%,38%,24%,pneumonia of radiation therapy is 14 examples and 12 examples,leukocyte in blood reaction is 26 examples and 17 examples,gastrointestinal effective is 25examples and 9 examples,death is 38 examples and 48 examples,treatment routine is better than compare routine (P＜0.05).Conclusion Radiation with PCF plan chemotherapy treat middle and late period carcinoma of esophagus have hish alive rate side effects and bad effects are low.